Sep 11, 2017|18 min readBy Randall C WillisSpecial Report on Infectious Disease: The fungus within usIs our arsenal evolving quickly enough to match its protean foe?
May 16, 2010|4 min readBy Jeffrey BouleyAstellas finally convinces OSI Pharmaceuticals to agree to merger after raising offer to $4 billionPer-share price of $57.50 represents 55 percent premium over closing price the day before Astellas made its previous $3.5 billion offer
May 23, 2010|4 min readBy Jeffrey BouleyAstellas Pharma finally woos OSI Pharmaceuticals with $4 billion offerFinal price falls short of $60 per share amount that some had predicted would be necessary to seal the deal